1-4 of 4
Rajyalakshmi Luthra, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 2734.
https://doi.org/10.1182/blood.V122.21.2734.2734
Published: 2013
Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 2562.
https://doi.org/10.1182/blood.V120.21.2562.2562
Published: 2012
Journal Articles

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Farhad Ravandi, MD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, Ph.D., Sherry A. Pierce, RN, BS, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Tapan M. Kadia, M.D., Naveen Pemmaraju, M.D., Naval Daver, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge E Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 2483.
https://doi.org/10.1182/blood.V120.21.2483.2483
Published: 2012
Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3781.
https://doi.org/10.1182/blood.V120.21.3781.3781
Published: 2012